dexmedetomidine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
835 113775-47-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dexmedetomidine
  • (S)-Medetomidine
  • dexmedetomidine hydrochloride
  • dexdor
  • dexmedetomidine HCl
  • MPV1440
A imidazole derivative that is an agonist of ADRENERGIC ALPHA-2 RECEPTORS. It is closely-related to MEDETOMIDINE, which is the racemic form of this compound.
  • Molecular weight: 200.29
  • Formula: C13H16N2
  • CLOGP: 3.11
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 28.68
  • ALOGS: -3.06
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 mg P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.09 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 1.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 11 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.06 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 17, 1999 FDA HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bradycardia 184.92 118.20 41 265 9940 2347839

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperthermia 172.11 129.14 32 317 1659 1744773
Bradycardia 156.49 129.14 41 308 10493 1735939

Pharmacologic Action:

SourceCodeDescription
ATC N05CM18 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Other hypnotics and sedatives
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058647 Adrenergic alpha-2 Receptor Agonists
MeSH PA D000316 Adrenergic alpha-Agonists
FDA MoA N0000009918 Adrenergic alpha2-Agonists
FDA EPC N0000175554 Central alpha-2 Adrenergic Agonist
FDA PE N0000175975 General Anesthesia
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
CHEBI has role CHEBI:35717 sedative
CHEBI has role CHEBI:35481 non-narcotic analgesic
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35569 alpha-adrenergic agonist
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D006993 Hypnotics and Sedatives
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Conscious sedation indication 314271007
Complete atrioventricular block contraindication 27885002
Hypovolemia contraindication 28560003
Hypertensive disorder contraindication 38341003 DOID:10763
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Diabetes mellitus contraindication 73211009 DOID:9351
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Cardiac Decompensation contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.36 acidic
pKa2 6.76 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) PRECEDEX HOSPIRA N021038 March 13, 2013 RX INJECTABLE INJECTION 8455527 Jan. 4, 2032 USE FOR SEDATION
EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) PRECEDEX HOSPIRA N021038 March 13, 2013 RX INJECTABLE INJECTION 8455527 Jan. 4, 2032 USE FOR SEDATION
EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) PRECEDEX HOSPIRA N021038 Nov. 14, 2014 RX INJECTABLE INJECTION 8455527 Jan. 4, 2032 USE FOR SEDATION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-2A adrenergic receptor GPCR AGONIST EC50 8.82 CHEMBL CHEMBL
Alpha-2C adrenergic receptor GPCR AGONIST Ki 9.30 IUPHAR CHEMBL
Alpha-2B adrenergic receptor GPCR AGONIST Ki 9.70 IUPHAR CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 6.70 PDSP
Alpha-1B adrenergic receptor GPCR Ki 6.50 PDSP
Alpha-1D adrenergic receptor GPCR Ki 10.82 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 8.30 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 10.82 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 10.82 CHEMBL

External reference:

IDSource
4021214 VUID
N0000148660 NUI
C0113293 UMLSCUI
D00514 KEGG_DRUG
1018WH7F9I UNII
145108-58-3 SECONDARY_CAS_RN
6277 INN_ID
438079000 SNOMEDCT_US
48937 RXNORM
d04505 MMSL
4021214 VANDF
437750002 SNOMEDCT_US
008084 NDDF
5311068 PUBCHEM_CID
CHEBI:4466 CHEBI
CHEMBL778 ChEMBL_ID
DB00633 DRUGBANK_ID
521 IUPHAR_LIGAND_ID
D020927 MESH_DESCRIPTOR_UI
CHEMBL2106195 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dexmedetomidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9525 INJECTION, SOLUTION 4 ug INTRAVENOUS ANDA 17 sections
Dexmedetomidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9526 INJECTION, SOLUTION 4 ug INTRAVENOUS ANDA 17 sections
Dexmedetomidine HCl HUMAN PRESCRIPTION DRUG LABEL 1 0143-9532 INJECTION 100 ug INTRAVENOUS ANDA 17 sections
DEXMEDETOMIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0338-9555 INJECTION 200 ug INTRAVENOUS ANDA 17 sections
DEXMEDETOMIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0338-9557 INJECTION 400 ug INTRAVENOUS ANDA 17 sections
Precedex HUMAN PRESCRIPTION DRUG LABEL 1 0409-1638 INJECTION, SOLUTION, CONCENTRATE 100 ug INTRAVENOUS NDA 17 sections
Precedex HUMAN PRESCRIPTION DRUG LABEL 1 0409-1660 INJECTION, SOLUTION 4 ug INTRAVENOUS NDA 17 sections
Dexmedetomidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-3297 INJECTION, SOLUTION 100 ug INTRAVENOUS ANDA 17 sections
Dexmedetomidine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-239 INJECTION, SOLUTION 100 ug INTRAVENOUS ANDA 17 sections
Dexmedetomidine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-432 INJECTION, SOLUTION 100 ug INTRAVENOUS ANDA 17 sections
Dexmedetomidine HUMAN PRESCRIPTION DRUG LABEL 1 17478-055 INJECTION, SOLUTION, CONCENTRATE 100 ug INTRAVENOUS ANDA 17 sections
Dexmedetomidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42023-146 INJECTION, SOLUTION, CONCENTRATE 100 ug INTRAVENOUS ANDA 18 sections
DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 43066-555 INJECTION 200 ug INTRAVENOUS ANDA 17 sections
DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 43066-557 INJECTION 400 ug INTRAVENOUS ANDA 17 sections
Dexmedetomidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 44567-600 INJECTION, SOLUTION, CONCENTRATE 100 ug INTRAVENOUS NDA 18 sections
Dexmedetomidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 44567-601 INJECTION, SOLUTION, CONCENTRATE 100 ug INTRAVENOUS NDA 18 sections
Dexmedetomidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 44567-602 INJECTION 4 ug INTRAVENOUS NDA 18 sections
Dexmedetomidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 44567-603 INJECTION 4 ug INTRAVENOUS NDA 18 sections
PRECEDEX HUMAN PRESCRIPTION DRUG LABEL 1 52584-638 INJECTION, SOLUTION, CONCENTRATE 100 ug INTRAVENOUS NDA 16 sections
Dexmedetomidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 55150-209 INJECTION, SOLUTION 100 ug INTRAVENOUS ANDA 17 sections
Dexmedetomidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 57664-596 INJECTION, SOLUTION 100 ug INTRAVENOUS ANDA 17 sections
DEXMEDETOMIDINE HUMAN PRESCRIPTION DRUG LABEL 1 57884-3091 INJECTION, SOLUTION, CONCENTRATE 100 ug INTRAVENOUS ANDA 17 sections
Dexmedetomidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63323-421 INJECTION, SOLUTION 100 ug INTRAVENOUS ANDA 18 sections
Dexmedetomidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 63323-671 INJECTION, SOLUTION 4 ug INTRAVENOUS ANDA 18 sections
Dexmedetomidine HUMAN PRESCRIPTION DRUG LABEL 1 67457-251 INJECTION, SOLUTION, CONCENTRATE 100 ug INTRAVENOUS ANDA 17 sections
DEXMEDETOMIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 68382-124 INJECTION, SOLUTION, CONCENTRATE 100 ug INTRAVENOUS ANDA 18 sections
DEXMEDETOMIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 70771-1319 INJECTION, SOLUTION, CONCENTRATE 100 ug INTRAVENOUS ANDA 18 sections
Dexmedetomidine HUMAN PRESCRIPTION DRUG LABEL 1 70860-605 INJECTION, SOLUTION, CONCENTRATE 100 ug INTRAVENOUS ANDA 17 sections
DEXMEDETOMIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 71225-126 INJECTION 4 ug INTRAVENOUS ANDA 17 sections
Dexmedetomidine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 71872-7030 INJECTION, SOLUTION 100 ug INTRAVENOUS ANDA 17 sections